Retrospective EGFR mutation testing of clinical specimens from the EURTAC trial of erlotinib in non-small cell lung cancer (NSCLC) using a novel allele-specific PCR (AS-PCR) assay.

Susana Benlloch,Miquel Taron,Maria Luisa Botero,Jordi Bertran-Alamillo,Clara Mayo,Ana Giménez-Capitán,Itziar de Aguirre,Cristina Queralt,Jose Luis Ramirez,Rafael Rosell,Barbara Klughammer,Mariette Schlegel,David Chen,Walter Bordogna,Ju Ruey-Jiuan Lee,Barbara Kovach,Patrick O'Donnell,Lin Wu,H. Jeffrey Lawrence

Retrospective EGFR mutation testing of clinical specimens from the EURTAC trial of erlotinib in non-small cell lung cancer (NSCLC) using a novel allele-specific PCR (AS-PCR) assay.

2017

Susana Benlloch
Miquel Taron
Maria Luisa Botero
Jordi Bertran-Alamillo
Clara Mayo
Ana Giménez-Capitán
Itziar de Aguirre
Cristina Queralt
Jose Luis Ramirez
Rafael Rosell
Barbara Klughammer
Mariette Schlegel
David Chen
Walter Bordogna
Ju Ruey-Jiuan Lee
Barbara Kovach
Patrick O'Donnell
Lin Wu
H. Jeffrey Lawrence

10596 Background: Anti-EGFR inhibitors are superior to chemotherapy in first-line therapy of advanced EGFR-mutant NSCLC. The EURTAC trial was a randomized Phase III trial of erlotinib vs. chemother...

Keywords:

Mutation testing
Oncology
Erlotinib
Internal medicine
non-small cell lung cancer (NSCLC)
Variants of PCR
Pathology
Medicine
Chemotherapy
pcr assay
egfr mutation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations